Clinical Oncology
Volume 22, Issue 5 , Pages 356-364 , June 2010

Continuous Hyperfractionated Accelerated Radiotherapy (CHART) and Non-conventionally Fractionated Radiotherapy in the Treatment of Non-small Cell Lung Cancer: a Review and Consideration of Future Directions

  • M.Q.F. Hatton

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: M.Q.F. Hatton, Department of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK. Tel: +44-114-226 5080; Fax: +44-114-226-5512.
    • ,
  • J.E. Martin

Received 5 March 2009 ,Revised 10 March 2010 ,Accepted 17 March 2010.

References 

  1. Patterson CJ, Hocking M, Bond M, et al. Retrospective study of radiotherapy for lung cancer in patients aged 75 years and over. Age Ageing. 1998;27:515–518
  2. Perez CA, Stanley K, Grundy G, et al. Impact of irradiation technique and tumour extent in tumour control and survival of patients with unresectable non-oat cell carcinoma of the lung: Report by the Radiation Therapy Oncology Group. Cancer. 1982;50:1091–1099
  3. Roswit B, Patno ME, Rapp R. The survival of patients with inoperable lung cancer: a large randomized study of radiation therapy verses placebo. Am J Roentgenol. 1968;90:688–697
  4. Wisnivesky JP, Bonomi M, Henschke C. Radiation therapy for the treatment of stage I–II non-small cell lung cancer. Chest. 2005;128:1461–1467
  5. Katz H, Alberts RW. A comparison of high dose continuous and split course irradiation in non-oat cell carcinoma of the lung. Am J Clin Oncol. 1983;6:445–457
  6. Arriagada R, Le Chevalier T, Quoix E, et al. Effect of chemotherapy on locally advanced non-small lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys. 1991;20:1183–1190
  7. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 1992;326:524–530
  8. Gouders D, Maingon P, Rodrigus P, et al. Exclusive radiotherapy for inoperable stage I non small cell lung cancer (NSCLC): a multi-centric study. Lung Cancer. 2000;29(Suppl. 1):166
  9. Perez CA, Bauer M, Edelstein S, Gillespie BW, Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 1986;12:539–547
  10. Large dose fractionation (hypo-fractionation). Proc Natl Conf Radiat Oncol Cancer. 1985;55S:2105–2111
  11. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131–146
  12. Maciejewski B, Withers HR, Taylor JMG, et al. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumour dose-response and repopulation. Int J Radiat Oncol Biol Phys. 1989;16:831–843
  13. Price A. Results of a survey of UK clinical oncologists. Presented at the Medical Research Council, 2001.
  14. Din OS, Harden SV, Hudson E, et al. Accelerated hypofractionated radiotherapy for non small cell lung cancer: pooled results from 4 UK centres. 13th World Conference on Lung Cancer P3:246.
  15. Lester JF, Macbeth FR, Brewster AE, et al. CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer. Lung Cancer. 2004;45:237–242
  16. Cheung PC, Mackillop WJ, Dixon P, et al. Involved-field radiotherapy alone for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2000;48:703–710
  17. Faria SL, Souhami L, Portelance L, et al. Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer. Radiat Oncol. 2006;1:42
  18. Pemberton LS, Din OS, Fisher PM, et al. Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome. Clin Oncol. 2009;21:161–167
  19. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87(3):198–205
  20. Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase II/III trial of hyper-fractionated radiation therapy with total doses of 60.0Gy to 79.2Gy. Possible survival benefit with ≥69.6Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small cell lung carcinoma. Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 1990;8:1543–1555
  21. Jeremic B, Milicic B. From conventionally fractionated radiation therapy to hyper-fractionated radiation therapy alone and with concurrent chemotherapy in patients with early stage non small cell lung cancer. Cancer. 2008;112:876–884
  22. Ball D, Bischop J, Smith J, et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol. 1999;52:129–136
  23. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Parmar M. Continuous, hyper-fractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol. 1999;52:137–148
  24. Din OS, Lester J, Cameron A, et al. The routine use of continuous, hyper-fractionated, accelerated radiotherapy (CHART) for non-small cell lung cancer: a five centre experience. Int J Radiat Oncol Biol Phys. 2008;72:716–722
  25. Saunders MI, Rojas A, Lyn BE, et al. Dose escalation with CHARTWEL (Continuous Hyper-fractionated Accelerated Radiotherapy Week End Less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. Clin Oncol. 2002;14:352–360
  26. Belani CP, Wang W, Johns DH, et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyper-fractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol. 2005;23:3760–3767
  27. NSCLC Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J. 1995;311:899–909
  28. Dillman RO, Seagreen SL, Propert KJ, et al. Randomised trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non small cell lung cancer. N Engl J Med. 1990;323:940–945
  29. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by chemo-radiotherapy compared with chemo-radiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukaemia Group B. J Clin Oncol. 2007;25:1698–1704
  30. Rowell NP, O'Rourke NP. Concurrent chemo-radiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2004;(4):
  31. Hanna NH, Neubauer M, Ansari R, et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. J Clin Oncol. 2007;25(18S):7512
  32. Kirkbride P, Hatton M, Fisher P, et al. Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer. Clin Oncol. 2002;14:361–366
  33. Oral EN, Bavbek S, Kizir A, et al. Preliminary analysis of a phase II study of paclitaxel and CHART in locally advanced non-small cell lung cancer. Lung Cancer. 1999;25:191–198
  34. Oner Dincbas F, Koca S, Altinel , et al. CHART plus chemotherapy with vinorelbine and cisplatinum in locally advanced NSCLC. Proc ECCO. 2001;a184
  35. Hatton M, Nankivell M, Lyn E, et al. Induction chemotherapy and continuous hyper-fractionated accelerated radiotherapy (CHART) for patients with locally advanced inoperable non-small cell lung cancer: the MRC INCH randomised trial. 13th World Conference on Lung Cancer B5.5.
  36. Baumann M, Herrmann T, Koch R, et al. Final results of the randomised phase III CHART-WEL trial (ARO 97-1) comparing hyper-fractionated accelerated vs conventionally fractionated radiotherapy in non-small-cell lung cancer. Eur J Cancer. 2009;7(S3):4LBA
  37. Maguire K, Kelly V, Page R, et al. Enhanced local control and survival with UK fractionation schedule for concurrent chemo-radiation in NSCLC. Proc Am Soc Clin Oncol. 2003;22:661;[abstract 2657]
  38. Maguire J. SOCCAR. A randomized phase III trial of sequential chemotherapy followed by radical radiotherapy versus concurrent chemo-radiotherapy followed by chemotherapy in patients with inoperable non small cell lung cancer and good performance status. ISCRTN: 13746987.
  39. Belerbos J, Uitterhoeve L, van Zandwijk , et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable lung cancer (EORTC 08972-22973). Eur J Cancer. 2007;43:114–121
  40. Price A, Yellowlees A, Faivre Finn C, et al. A randomized trial of radical radiotherapy with or without low dose gemcitabine in patients with T1-2 N0-1 M0 non small cell lung cancer. 13th World Conference on Lung Cancer PD12.4.8.
  41. Blackstock AW, Govindan R. Definitive chemoradiation for the treatment of locally advanced non-small cell lung cancer. J Clin Oncol. 2007;25:4146–4152
  42. Kelly K, Chansky K, Gaspar LE, et al. Updated analysis of SWOG 0023: a randomized phase II trial of gefitinib versus placebo maintenance after definitive chemo-radiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. J Clin Oncol. 2007;25(Suppl.):7513
  43. Kong FM, Ten Haken RK, Schipper MJ, et al. High dose radiation improved local tumour control and overall survival in patients with inoperable/unresectable non small cell lung cancer: long term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:324–333
  44. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005;61(2):318–328
  45. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non small cell lung carcinoma. Cancer. 2005;103:2118–2127
  46. McGibney C, Holmberg O, McClean B, et al. Dose escalation of CHART in NSCLC: is three dimensional conformal radiation therapy really necessary?. Int J Radiat Oncol Biol Phys. 1999;45:339–350
  47. Mehta MP, Tannehill SP, Adak S, et al. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593. J Clin Oncol. 1998;16:3518–3523
  48. Sibley GS, Maguire PD, Anscher MA, Light K, Antoine P, Marks LB. High-dose accelerated radiotherapy for non-small cell lung cancer: 7360cGy and beyond. Int J Radiat Oncol Biol Phys. 1999;45:241
  49. Du Ruysscher D, Wanders R, Van Haren E, et al. Hi-CHART: a phase I/II study on the feasibility of high-dose continuous hyper-fractionated accelerated radiotherapy in patients with in-operable non small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;71:132–138
  50. Van Baardwijk A, Bosmans G, Boersma L, et al. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys. 2008;71:1394–1401
  51. Thirion P, Holmberg O, Collins CD, et al. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. Radiother Oncol. 2004;71:163–166
  52. Belderbos JSA, De Jaeger K, Heemsbergen WD, et al. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:126–134
  53. Lagerwaard FJ, Haasbeek CJ, Smit EF, et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;71:1118–1123
  54. Onimaru R, Shirato H, Shimizu S, et al. Tolerance of organs at risk in small-volume, hypofractionated, image guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys. 2003;56:126–135
  55. Timmerman R, Papriez L, McGarry R, et al. Extra-cranial stereotactic radio-ablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124:1946–1955
  56. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I non small cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multi-institutional study. Cancer. 2004;101:1623–1631
  57. Wulf J, Hadinger U, Oppitz U, et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 2004;60:186–196
  58. Hoyer M. Prospective study on stereotactic radiotherapy of limited stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2005;63:S396
  59. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63:1427–1431
  60. Beitler JJ, Badine EA, El-Sayah D, et al. Stereo-tactic body radiation therapy for non-metastatic lung cancer: an analysis of 75 patients treated over 5 years. Int J Radiat Oncol Biol Phys. 2006;65:100–106
  61. Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66:117–125
  62. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45:787–795
  63. Zimmermann FB, Geinitz H, Schill S, et al. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol. 2006;45:796–801
  64. Faria SL, Souhami L, Portelance L, et al. Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer. Radiat Oncol. 2006;1:42
  65. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51:666–670
  66. Hof H, Meunter M, Oetzel , et al. Stereotactic single dose radiotherapy of early stage non small cell lung cancer. Cancer. 2007;110:148–155
  67. Ball D. CHISEL. A randomised phase III trial of highly conformal hypofractionated image guided (stereotactic) radiotherapy versus conventionally fractionated radiotherapy for inoperable early stage non-small cell lung cancer. Trans Tasman Radiation Oncology Group: A0031029V.
  68. Senan S. ROSEL. A randomized clinical trial of surgery versus radiosurgery (stereotactic radiotherapy) in patients with stage IA NSCLC who are fit to undergo primary resection, 2008. ClinicalTrials.gov identifier: NCT00687986.
  69. Seppenwoolde Y, Lebesque JV, de Jaeger K, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2003;55:724–735
  70. Hatton M. CHART-ED. Phase I study of Continuous Hyperfractionated Accelerated RadioTherapy – escalated dose study. ISRCTN; 2009;45918260

PII: S0936-6555(10)00122-6

doi: 10.1016/j.clon.2010.03.010

Clinical Oncology
Volume 22, Issue 5 , Pages 356-364 , June 2010

Article Tools